Kalaris Therapeutics's total assets for Q3 2025 were $81.17M, a decrease of -12.57% from the previous quarter. KLRS total liabilities were $39.31M for the fiscal quarter, a -1.05% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.